• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Biologics and Biosimilars World Markets - Product Image

Biologics and Biosimilars World Markets

  • ID: 2622741
  • August 2013
  • Region: Global
  • 403 Pages
  • TriMark Publications
Global Biologic Drugs Market to Jump to Over $220 Billion by 2019

FEATURED COMPANIES

  • Abbott Laboratories
  • Apotex, Inc
  • Biocon Ltd
  • Celltrion, Inc
  • Gilead Sciences, Inc
  • Mylan, Inc
  • MORE

Biologics are complex molecules manufactured through cell culture recombinant DNA technology. Biologics additionally comprise recombinant insulin, growth hormone and monoclonal antibodies for treating conditions such as cancer and autoimmunity. Also known as follow-on biologics or subsequent entry biologics (SEBs), biosimilars are to biologics what generics are to branded drugs; they lower healthcare expenditures. This report anticipates that the global biologic drugs market will jump to over $220 billion by 2019.

The study describes the emergence of biologics and biosimilars and their potential role in shaping the future of the global healthcare industry. The study analyzes the changing dynamics of the pharmaceutical market and provides insight into the regulatory pathways for branded pharmaceuticals and biologics, patent expirations, business strategies, clinical trials and drug applications.

Biologics, also known as biopharmaceuticals, can be categorized into three main modalities: therapeutic proteins, monoclonal antibodies and vaccines. Most of the biologic drugs marketed so far are recombinant therapeutic protein drugs, which are used to relieve patients suffering READ MORE >

Note: Product cover images may vary from those shown
Global Biologic Drugs Market to Jump to Over $220 Billion by 2019

FEATURED COMPANIES

  • Abbott Laboratories
  • Apotex, Inc
  • Biocon Ltd
  • Celltrion, Inc
  • Gilead Sciences, Inc
  • Mylan, Inc
  • MORE

1. Overview
1.1 Statement of This Report
1.2 About This Report
1.3 Scope of the Report
1.4 Objectives
1.5 Methodology
1.6 Executive Summary

2. Pharmaceutical Industry: An Overview
2.1 Global R&D Spending by Pharma and Biotech Companies
2.1.1 Top 20 Companies in R&D Spending
2.1.2 Top 20 Most Valuable Pharmaceutical R&D projects
2.1.3 Most Valuable R&D Projects Ranked by Net Present Value
2.2 FDA New Drug Approvals
2.2.1 Top Ten NMEs
2.3 Impact of Patent Expirations
2.4 Immunity of Pharmaceutical Growth against Drop in GDP Growth
2.5 Minimal Annual Growth Rates of Pharmaceuticals in Developed Markets
2.6 Falling Operating Profit Rate for Big Pharma
2.7 Top Ten Global Pharmaceutical Firms
2.6 Top Ten Pharmaceuticals by Sales Revenue
2.7 Worldwide Prescription and OTC Sales by Therapy Area in 2018
2.8 Top Companies in Oncology Sales
2.8.1 Top Five Oncology Products
2.9 Top Companies in Anti-Diabetes Market
2.9.1 Top Five Anti-Diabetes Products
2.10 Top Ten Companies in Anti-Rheumatics Market
2.10.1 Top Ten Anti-Rheumatics Products
2.11 Top Ten Vaccine Companies and Global Sales
2.11.1 Top Five Vaccine Products
2.12 Top Ten Anti-Viral Companies
2.12.1 Top Five Anti-Viral Products
2.13 Top 50 Global Pharmaceutical Brands in 2018
2.14 M&A Transactions in 2012
2.15 Global Pharmaceutical Market
2.15.1 Global Pharmaceutical Sales by Region
2.15.2 North American Pharmaceutical Market
2.15.2.1 U.S. Prescription Drug Sales by Company
2.15.2.2 Top 50 Pharmaceutical Products in the U.S.
2.15.2.3 Top 50 Products in the U.S. in 2018
2.15.3 Pharmaceutical Market in Europe
2.15.3.1 European Prescription Drug Sales by Company
2.15.4 Pharmaceutical Market in Asia/Pacific
2.15.4.1 Prescription Drug Sales in Japan by Company
2.15.5 Pharmaceutical Market in Latin America
2.15.6 Pharmaceutical Market in Africa
2.15.7 Pharmaceutical Market in the Middle East
2.16 Regional Prescription Drug Sales in the U.S., Europe and Japan
2.17 Global Prescription Drug Sales

3. Brand Name Pharmaceuticals: A Brief Overview
3.1 Birth Pangs and Life Span of Branded Drugs
3.2 Major Patent Expiries of Branded Drugs
3.3 Global Market for Branded Drugs
3.4 Increasing R & D Pipeline
3.4.1 The 2012 R & D Pipeline by Phase
3.4.2 Top Companies by Pipeline Size
3.4.3 Total Number of Companies with Active R&D
3.4.4 Global Distribution of Companies Active in Pharma R&D
3.4.5 Top Therapy Areas in R & D
3.4.5.1 Top 25 Individual Diseases in the R & D Pipeline
3.4.6 Top 20 Mechanism of Action in R & D Pipeline
3.4.7 Top 25 Drug Protein Targets

4. Generic Drugs: A Brief Overview
4.1 Bioequivalence of Generics
4.2 Global Market for Generics
4.3 Operating Profit Rate for Generic Companies
4.4 Outsourced Manufacture of Generics
4.5 Generic Utilization in International Markets
4.6 Global Generic Sales by Company

5. Biologics
5.1 Regulations for Biologics
5.2 Complexity of Biologics
5.3 Concentration of Global Biopharmaceutical Manufacturing
5.4 Number of Biologics Available in the Global Market
5.5 Share of Biologics by Country/Region
5.6 Rate of Growth for Biologics by Region
5.6.1 Growth Rates of APIs and Biologics Compared
5.7 Manufacturing Capacity of Biologics
5.8 Biologics Market by Segment
5.9 Patent Expiry for Biologic Drugs
5.9.1 India's Opportunity from Biologic Patent Expirations
5.10 Major Players in Biologics
5.11 Biopharm Outsourcing
5.12 Top 20 Biologics by Sales
5.12.1 Roche's Biologics Arsenal
5.12.2 Johnson & Johnson's Biologics Arsenal
5.12.3 Lonza in Biologics
5.13 The Best Selling Biologics by Class
5.14 Biologic Drugs: Market Trends in the Past Seven Years
5.14.1 Global Market for Biologics
5.15 Global and U.S. Sales of Blockbuster Biologics
5.15.1 Global Market for Humira
5.15.1.1 Humira (adalimumab) Pen's Market by Geography
5.15.1.2 U.S. Sales of Humira
5.15.1.3 The Leader among Biologics
5.15.2 Global Market for Remicade
5.15.2.1 Remicade's Market by Geography
5.15.2.2 U.S. Sales of Remicade
5.15.3 Global Market for Enbrel
5.15.3.1 Enbrel's Market by Geography
5.15.3.2 U.S. Sales of Enbrel
5.15.4 Global Market for Symponi
5.15.5 Global Market for Tysarbi
5.15.5.1 U.S. Market for Tysarbi
5.15.6 Global Market for Lantus
5.15.6.1 Lantus' Market by Geography
5.15.6.2 U.S. Market for Lantus
5.15.7 Global Market for NovoRapid
5.15.7.1 Market for Novolog/Novorapid by Geography
5.15.7.2 U.S. Market for NovoRapid
5.15.8 Global Market for Victoza
5.15.9 Global Market for Levemir
5.15.9.1 U.S. Market for Levemir
5.15.10 Global Market for Humalog
5.15.10.1 Market for Humalog by Geography
5.15.11 Global Market for Neulasta
5.15.11.1 Neulasta's Market by Geography
5.15.11.2 U.S. Market for Neulasta
5.15.12 Global Market for Privigen
5.15.13 Global Market for Perjeta
5.15.14 Global Market for Xgeva/Prolia
5.15.15 Global Market for Soliris
5.15.15.1 U.S. Market for Soliris
5.15.16 Global Market for Botox
5.15.17 Global Market for Lucentis
5.15.17.1 U.S. Market for Lucentis
5.15.18 Global Market for Eylea
5.15.19 Global Market for Avastin
5.15.19.1 U.S. Market for Avastin
5.15.20 Global Market for Rituxan
5.15.20.1 Rituxan's Market by Geography
5.15.20.2 U.S. Market for Rituxan
5.15.21 Global Market for Revlimid
5.15.22 Global Market for Herceptin
5.15.22.1 Herceptin's Market by Geography
5.15.21.2 U.S. Market for Herceptin
5.15.22 Global Market for Prenvar 13
5.15.22.1 U.S. Market for Prenvar 13
5.15.23 Global Market for Gardasil
5.15.24 Global Market for Fluzone/Varigrip
5.15.25 Global Market for Varivax
5.15.26 Global Market for Stelara
5.15.26.1 U.S. Market for Stelara
5.15.27 Global Market for Actemra
5.15.28 Global Market for Gammagard Liquid
5.16 The U.S. Biotech Landscape
5.16.1 Top U.S. Biotech Companies
5.16.1.1 Amgen
5.16.1.2 Gilead Sciences
5.16.1.3 Biogen Idec, Inc.
5.16.1.4 Celgene Corporation
5.16.1.5 Genzyme (Sanofi)
5.16.1.6 Life Technologies Corporation
5.16.1.7 Cephalon, Inc/Teva Pharmaceutical Industries Ltd.
5.16.1.8 Alexion Pharmaceuticals, Inc.
5.16.1.9 Cubist Pharmaceuticals, Inc.
5.16.1.10 United Therapeutics Corporation
5.16.2 Overall Performance of the U.S. Biotech Companies
5.16.3 R & D Spending by Biotech Companies in the U.S.
5.16.4 U.S. Market for Biologic Drugs
5.16.5 The Leading Biologic Drug Classes in Terms of U.S. Sales
5.16.5.1 Top Selling Biologic Drugs in the U.S.
5.16.5.2 U.S. Sales of Biologics by Manufacturer
5.16.6 U.S. Sales of mAbs
5.16.7 U.S. Sales of Recombinant Hormones
5.16.8 U.S. Sales of Blood Cell Growth Factors
5.16.9 U.S. Market for Cytokines
5.16.10 U.S. Sales of Blood Factors
5.16.11 U.S. Sales of Therapeutic Enzymes
5.16.12 U.S. Sales of Recombinant Vaccines
5.16.13 U.S. Sales of Recombinant Anticoagulants
5.16.14 Costs of Commonly Used Biologicals in the U.S.
5.16.15 Biologics Used for Treating Rheumatoid Arthritis
5.16.15.1 Cost Comparison of Arthritis Biologics
5.17 Biologics in Europe
5.17.1 Uptake of Biologics in Europe by Drug Type
5.17.2 European Market for mAbs
5.18 Biologics in Hemophilia
5.18.1 Marker Leaders in Hemophilia
5.18.2 Hemophilia A
5.18.3 Hemophilia B
5.18.4 Inhibitors

6. Biosimilars
6.1 Different Names in Different Countries for Biologics
6.2 E.U. Approval Pathway for Biosimilars
6.3 Contentious Issues in Biosimilars
6.4 Biosimilars Opportunity
6.5 Challenges in Biosimilar Introduction
6.6 Production and Market Access of Biosimilars
6.7 Country Selection for Biosimilars
6.8 High Barriers to the Entry of Biosimilars
6.9 Global Competition among Biosimilars
6.10 Definitions and Interpretations of Biosimilar Products
6.10.1 Regulatory Requirements
6.10.1.1 World Health Organization (WHO)
6.10.1.2 Key Principles and Basic Concept
6.10.2 Reference Biotherapeutic Product
6.10.2.1 Quality
6.10.2.2 Non-Clinical and Clinical Studies
6.10.3 E.U.
6.10.3.1 Key Principles and Basic Concept
6.10.3.2 Reference Biotherapeutic Product
6.10.3.3 Quality
6.10.3.4 Non-Clinical and Clinical Evaluation
6.10.3.5 Product Class-Specific Guidelines
6.10.4 U.S.
6.10.5 Canada
6.10.6 Japan
6.10.7 Korea
6.11 FDA Guidelines for Biosimilars
6.12 Market Drivers
6.12.1 Cost Pressures
6.13 Core Therapy Areas for Biosimilars
6.14 Competitive Landscape in Biosimilar Sector
6.15 Opportunities for Biosimilars in Three Geographies
6.15.1 Opportunities for Biosimilars in the U.S.
6.15.2 European Opportunities for Biosimilars
6.15.3 Opportunities for Biosimilars in Emerging Markets
6.16 Biosimilar Experience
6.17 Development of Biosimilars
6.17.1 Current and Future Trends in Biosimilar Development
6.18 Top Players in Biosimilars Market
6.18.1 Other Key Players in Biosimilars Market
6.19 Number of Biologics Patent Expiries Prior to 2020
6.19.1 Biologics Patent Expiries by Region
6.20 Monoclonal Antibodies: The Key Focus Area for Biosimilars Development
6.20.1 Biosimilar mAbs in Pipeline
6.20.2 Disease Indications for Biosimilar mAbs
6.21 Global Leaders in Biosimilars
6.22 Market Leading Biosimilars
6.23 Biosimilar Opportunities: Only for the Heartiest Biotech Firms
6.24 Biosimilars Pipeline by Class
6.25 Global Biosimilars Market
6.25.1 Estimated Value and Growth Rates for Biosimilars by Type
6.25.2 Market Leading Biosimilars in 2015
6.26 Regulations for Biosimilars in the U.S.
6.26.1 BPCIA and Guidance
6.26.2 Scientific Considerations
6.26.3 Quality Considerations
6.26.4 Biosimilar User Fee Act
6.26.5 12-Year Exclusivity Period
6.26.6 Biosimilars Competitive Landscape in the U.S.
6.26.7 Manufacturing Capabilities
6.26.8 Clinical Trial Experience
6.26.9 Market Experience
6.26.10 Likely Early Entrants
6.26.11 Recombinant Protein Competition
6.26.12 mAbs Competition
6.27 U.S. Biosimilars Market
6.27.1 HGH Biosimilars in the U.S. Market
6.27.2 Cost Benefits from Biosimilars for U.S. Healthcare
6.27.3 Development Pipeline and Market Evolution of Biosimilars in the U.S.
6.27.3.1 Target Reference Products
6.27.3.2 Launchable Dates for Biosimilars in the U.S.
6.27.3.3 Number of Biosimilar Products in the Pipeline
6.28 Geographic Distribution of Biosimilars Pipeline
6.28.1 Developers of Biosimilars
6.29 Future of U.S. Biosimilars Market
6.29.1 Future Pricing Models
6.29.2 Future Price Reduction and the Profit Margin
6.30 Biosimilars Market in Europe and Japan
6.30.1 The Instant Growth of Biosimilars in Europe
6.30.2 Biosimilar mAbs on the Horizon in Europe
6.30.3 Biosimilars Approved in the E.U
6.30.4 Utilization of G-CSF in Europe
6.31 Revenue Forecast for Biosimilar Insulins
6.32 Revenue Forecast for Biosimilar HGH
6.33 Revenue Forecast for Biosimilar IFN Alpha
6.34 Revenue Forecast for Biosimilar IFN Beta Ia
6.35 Revenue Forecast for Biosimilar Filgrastim
6.36 Revenue Forecast for Biosimilar Epoetin Alpha
6.37 Uptake of Biosimilars in Europe
6.38 Biosimilars in China
6.38.1 Biosimilars Sales in China
6.39 Indian Market for Biosimilars
6.39.1 Domestic Biosimilar Developers in India
6.40 Biosimilar Pipeline of Celtrion in Korea
6.41 Deals in Biosimilar Space
6.41.1 Technologies
6.41.2 Manufacturing Agreements
6.41.3 Clinical Development
6.41.4 Licensing Agreements
6.42 Transactions in Biosimilars Industry
6.42.1 Biosimilars Market: Opportunities and Challenges
6.42.2 Recent Transactions in Biosimilars Industry
6.43 Top Ten Biosimilar Drugs to Watch
6.43.1 Aranesp (darbepoetin alfa)
6.43.2 Enbrel (etanercept)
6.43.3 Epogen/Procrit/Eprex/Erypo (epoetin alfa)
6.43.4 Genotropin (somatropin)
6.43.5 Herceptin (trastuzumab)
6.43.6 Humira (adalimumab)
6.43.7 Neulasta (pegfilgrastim)
6.43.8 Neupogen (filgrastim)
6.43.9 Remicade (infliximab)
6.43.10 Rituxan/MabThera (rituximab)

7. Company Profiles
7.1 3Bio, Inc.
7.1.1 EPIAO
7.1.2 TPIAO
7.1.3 INTEFEN
7.1.4 INLEUSIN
7.1.5 IV Iron Sucrose
7.2 Abbott Laboratories
7.3 AbbVie, Inc.
7.3.1 Products
7.4 Actelion Ltd.
7.5 Amgen, Inc.
7.5.1 Neulasta (filgrastim)
7.5.2 Enbrel (etanercept)
7.5.3 Aranesp (darbepoetin alfa)
7.5.4 Epogen (epoetin alfa)
7.5.5 Sensipar/Mimpara (cinacalcet)
7.5.6 Vectibix (panitumumab)
7.5.7 Nplate (romiplostim)
7.5.8 Prolia/Xgeva (denosumab)
7.6 Amoytop Biotech Co., Ltd
7.6.1 Molgramostim (rhGM-CSF)
7.6.2 Filgrastim (rh G-CSF)
7.6.3 Oprelvekin (rhIL-11)
7.7 Anhui Anke Biotechnology (Group) Co., Ltd.
7.7.1 Alteferon alpha 2b Injection
7.7.2 Ansomone
7.7.3 Anteferon alpha 2b Cream
7.7.4 Anteferon alpha 2b Eyedrop
7.8 Apotex, Inc.
7.9 Astellas Pharma, Inc.
7.10 AstraZeneca
7.10.1 AstraZeneca's R&D Portfolio
7.10.2 Patent Expiries of AstraZenecas Products
7.11 Bayer AG
7.12 Beijing Four Rings Biopharmaceuticals
7.12.1 Products
7.13 Bharat Serums and Vaccines Limited
7.14 Biocon Ltd.
7.15 Biogen Idec, Inc.
7.16 Bioton SA
7.17 Boehringer Ingelheim Pharmaceuticals, Inc.
7.18 Bristol-Myers Squibb, Co.
7.19 Celgene Corporation
7.20 Celltrion, Inc.
7.20.1 Technology Overview
7.20.2 Biosimilars Development
7.20.3 Contract Manufacturing
7.21 Cipla Ltd.
7.21.1 Cipla's Prescription Product Category
7.22 Dr. Reddy's Laboratories Ltd.
7.23 Elan Corporation, PLC
7.23.1 Tysarbi
7.24 Eli Lilly & Co.
7.25 Gideon Richter
7.26 Gilead Sciences, Inc.
7.27 GlaxoSmithKline PLC
7.28 Hospira, Inc.
7.29 Intas Pharmaceuticals Limited
7.30 Johnson & Johnson
7.31 Merck & Co., Inc.
7.32 Mylan, Inc.
7.32.1 Mylan's Generics
7.32.2 Mylan's Active Pharmaceutical Ingredients
7.32.3 Mylan's Specialty
7.32.4 Mylan's Anti-Retroviral Franchise
7.33 Novartis AG
7.34 Pfizer, Inc.
7.35 Roche Holdings AG
7.36 Sandoz International GmbH
7.37 Sanofi
7.38 Stada Arzneimittel Aktiengesellschaft
7.39 Teva Pharmaceutical Industries Limited
7.40 Watson Pharmaceuticals, Inc.

APPENDIX

Appendix 1: Biologic Medicines by Development Phase
Appendix 2: Declining Medicine Use in the U.S.
Appendix 2.1: Changes in Utilization
Appendix 2.2: Healthcare Costs and Spending on Medicines
Appendix 2.3: Total Spending on Medicines
Appendix 2.4: Transformations in Disease Treatment
Appendix 2.5: Key Breakthrough Therapies Approved in 2012
Appendix 2.5.1: Cystic Fibrosis: ivacaftor (Kalydeco)
Appendix 2.5.2: Rheumatoid Arthritis: tofacitinib (Xeljanz)
Appendix 2.5.3: Basal-cell carcinoma: vismodegib (Erivedge)
Appendix 2.5.4: Irritable bowel syndrome with constipation: linaclotide (Linzess)
Appendix 2.5.5: HIV: emtricitabine and tenofovir disoproxil fumarate (Truvada)
Appendix 2.5.6: Combination of elvitegravir, cobicistat, emtricitabine and tenofovir disoproxil fumarate
Appendix 2.6: Spending in Major Therapies
Appendix 2.6.1: Oncology Spending (25.9 Billion) by Area, 2012
Appendix 2.6.1.1: U.S. Market for Oncology Drugs
Appendix 2.6.1.2: U.S. Market for Rituxan
Appendix 2.6.1.3: U.S. Market for Avastin
Appendix 2.7: Mental Health Spending by Area
Appendix 2.7.1: U.S. Market for Mental Health Drugs
Appendix 2.7.2: U.S. Market for Cymbalta
Appendix 2.7.3: U.S. Market for Abilify
Appendix 2.8: Respiratory Spending by Area
Appendix 2.8.1: U.S. Market for Respiratory Drugs
Appendix 2.8.2: U.S. Market for Adavir
Appendix 2.8.3: U.S. Market for Singulair
Appendix 2.8.4: U.S. Market for Spiriva
Appendix 2.9: Antidiabetes Spending by Area
Appendix 2.9.1: U.S. Market for Antidiabetics
Appendix 2.9.2: U.S. Market for Januvia
Appendix 2.9.3: U.S. Market for Lantus
Appendix 2.9.4: U.S. Market for Lantus SoloSTAR
Appendix 2.10: Pain Spending by Area
Appendix 2.10.1: U.S. Market for Pain Management Drugs
Appendix 2.11: U.S. Market for Medicines Used in Nervous System Disorders
Appendix 2.11.1: U.S. Market for Oxycontin
Appendix 2.11.2: U.S. Market for Lyrica
Appendix 2.11.3: U.S. Market for Copaxone
Appendix 2.12: U.S. Market for Lipid Regulators
Appendix 2.12.1: U.S. Market for Crestor
Appendix 2.13: U.S. Market for Autoimmune Drugs
Appendix 2.13.1: U.S. Market for Humira
Appendix 2.13.2: U.S. Market for Enbrel
Appendix 2.13.3: U.S. Market for Remicade
Appendix 2.14: U.S. Market for Medicines Used for Multiple Sclerosis
Appendix 2.15: U.S. Market for Antiulcerants
Appendix 2.15.1: U.S. Market for Nexium
Appendix 2.16: U.S. Market for Neulasta
Appendix 2.17: U.S. Market for Epogen
Appendix 2.18: U.S. Market for Platelet Aggregation Inhibitors
Appendix 2.18.1: U.S. Market for Plavix
Appendix 2.19: U.S. Market for HIV Antivirals
Appendix 2.19.1: U.S. Market for Atripla
Appendix 2.19.2: U.S. Market for Truvada
Appendix 2.20: U.S. Market for Antibacterials
Appendix 2.21: U.S. Market for Antihypertensives
Appendix 2.21.1: U.S. Market for Diovan
Appendix 2.22: U.S. Market for ADHD
Appendix 2.23: U.S. Market for Vaccines (Pure, Comb and Others)
Appendix 2.24: U.S. Market for Systemic Hormonal Contraceptives
Appendix 2.25: Number of Treated Patients in Selected Therapies in the U.S.
Appendix 2.26: Top Therapeutic Classes of Drugs Prescribed in the U.S.
Appendix 2.27: Top Medicines Prescribed in the U.S.
Appendix 3: Pharma Deals in 2012
Appendix 4: Pharma Outsourcing in Asia
Appendix 4.1: Cluster One: Pharma Revenue Constraints
Appendix 4.2: Cluster Two: Asia Growth Forces
Appendix 4.3: Cluster Three: East/West Convergence/Divergence Trends
Appendix 4.4: Cluster Four: Technological/Business Model Forces
Appendix 4.5: Implications of the Four Clusters for Asia Outsourcing
Appendix 4.5.1: Rapid Expansion of Clinical Trials in Asia
Appendix 4.5.2: Manufacturing Scales
Appendix 4.5.3: Risk and Opportunity Overview
Appendix 4.5.4: Cost Ranking of Asian Territories
Appendix 4.5.5: Market Opportunity Ranking
Appendix 4.6: Outsourcing Hot Spots in Asia
Appendix 4.6.1: China
Appendix 4.6.2: India
Appendix 4.6.3: Singapore
Appendix 5: The Changing Payment Landscape for the U.S. Pharmaceutical Industry
Appendix 5.1: The Impetus for Defining Value
Appendix 5.1.1: Force I
Appendix 5.1.2: Force II
Appendix 5.1.3: Force III
Appendix 5.1.4: Force IV
Appendix 5.1.5: Force V
Appendix 5.2: The New Arbiters of Value
Appendix 5.2.1: Prescribers Looking for Value
Appendix 5.2.2: More Investment in Comparative Effectiveness Research
Appendix 5.2.3: Unleashing of Imprisoned Value
Appendix 5.2.4: Role of Companion Diagnostics
Appendix 5.2.5: Outcomes-Dependent Contracts
Appendix 5.2.6: Data-Sharing Agreements
Appendix 5.2.7: Patient-Reported Outcomes
Appendix 5.2.8: Evidence Needed to Secure Formulary Slots
Appendix 6: Medical Cost Trend in the U.S., 2013
Appendix 6.1: The Components of Medical Cost
Appendix 6.2: Leading Factors in Setting Insurance Premiums
Appendix 6.3: Factors Affecting 2013 Trend
Appendix 6.3.1: Medical Supply and Equipment Cost
Appendix 6.3.2: Newer Delivery Methods for Primary Care
Appendix 6.4: Uptick in Utilization and Expensive Advances
Appendix 6.4.1: Economic Utilization and Economic Growth
Appendix 6.4.2: Medical Advances Driving Growth
Appendix 6.4.3: The “New Normal”
Appendix 6.4.4: Current Practices by Employers
Appendix 6.4.4.1: Things to be considered by Employers
Appendix 6.5: Current Practices by Providers
Appendix 6.5.1: Things to be considered by Providers
Appendix 6.6: Current Practices by Hwealth Insurers
Appendix 6.6.1: Things to be considered by Health Insurers
Appendix 6.7: Current Practices by Pharmaceutical and Life Sciences
Appendix 6.7.1: Things to be considered by Pharmaceutical and Life Sciences
Appendix 7: Naming of Drug Molecules and Pharmaceutical Brands
Appendix 7.1: Names of a Drug
Appendix 7.1.1: Chemical Name
Appendix 7.1.2: Generic Name
Appendix 7.2: Brand Name
Appendix 7.2.1: Criteria for Brand Names
Appendix 7.3: Stories behind Some Blockbuster Molecules

INDEX OF FIGURES

Figure 2.1: Global R&D Spending by Pharma and Biotech Companies, 2005-2018
Figure 2.2: Worldwide Sales at Risk by Patent Expiration, 2004-2018
Figure 2.3: Immunity of Pharmaceutical Growth against Drop in GDP Growth
Figure 2.4: Falling Operating Profit Rate for Big Pharma
Figure 2.5: Global Pharmaceutical Market, 2012-2019
Figure 2.6: Global Pharmaceutical Sales by Region
Figure 2.7: North American Pharmaceutical Market, 2012-2019
Figure 2.8: European Pharmaceutical Market, 2012-2019
Figure 2.9: Pharmaceutical Market in Asia/Pacific, 2012-2019
Figure 2.10: Pharmaceutical Market in Latin America, 2012-2019
Figure 2.11: Pharmaceutical Market in Africa, 2012-2019
Figure 2.12: Pharmaceutical Market in the Middle East, 2012-2019
Figure 2.13: Worldwide Total Prescription Drug Sales, 2004-2018
Figure 3.1: The Long-Drawn R & D Process for Branded Drugs
Figure 3.2: Global Market for Branded Drugs, 2012-2019
Figure 3.3: R & D pipeline, 2001-2012
Figure 3.4: R & D Pipeline by Phase, 2007-2012
Figure 3.5: Total Number of Companies with Active R & D, 2000-2012
Figure 3.6: Global Distribution of Companies Active in Pharma R&D, 2012
Figure 4.1: Differences between Originals and Copies (Branded/Generics & Biologics/Biosimilars)
Figure 4.2: Global Market for Generics, 2012-2019
Figure 4.3: Operating Profit Rate for Top Six Generic Companies, 2006-2012
Figure 4.4: Outsourced Manufacturing of Generics by Region/Country
Figure 4.5: Generic Drug Use in International Markets
Figure 5.1: The Biologic Drug Development Process
Figure 5.2: Comparison of Small Molecule Drugs and Biologics
Figure 5.3: Concentration of Global Biopharmaceutical Manufacturing as of 2013
Figure 5.4: Share of Biologics Sales by Country/Region
Figure 5.5: Rate of Growth for Biologics by Region
Figure 5.6: Growth Rates (CAGR) of APIs and Biologics Compared
Figure 5.7: Global Installed Biopharmaceutical Manufacturing Capacity by Top Ten Companies
Figure 5.8: Biologics Market by Segment
Figure 5.9: Top Biologics Losing Patent Protection and Market Exclusivity Prior to 2018
Figure 5.10: Global Value and Number of Biologic Drugs Losing Patent Protection, 2010-2015
Figure 5.11: Top Ten Biopharmaceuticals Manufacturing Companies
Figure 5.12: Outsourcing Trends in Biological Production across All Cell-Based Platforms
Figure 5.13: The Largest Selling Biologics by Class, 2012
Figure 5.14: Global Biologic Drugs Market Trends, 2006-2012
Figure 5.15: Global Market for Biologics, 2010-2020
Figure 5.16: Global Market for Humira, 2012-2019
Figure 5.17: Humira Pen's Market by Geography
Figure 5.18: U.S. Market for Humira, 2012-2019
Figure 5.19: Global Market for Remicade, 2012-2019
Figure 5.20: Remicade's Market by Geography
Figure 5.21: U.S. Market for Remicade, 2012-2019
Figure 5.22: Global Market for Enbrel, 2012-2019
Figure 5.23: Enbrel's Market by Geography
Figure 5.24: U.S. Market for Enbrel, 2012-2019
Figure 5.25: Global Market for Simponi, 2012-2019
Figure 5.26: Global Market for Tysarbi, 2012-2019
Figure 5.27: U.S. Market for Tysabri, 2012-2019
Figure 5.28: Global Market for Lantus, 2012-2019
Figure 5.29: Lantus' Market Share by Geography
Figure 5.30: U.S. Market for Lantus, 2012-2019
Figure 5.31: Global Market for NovoRapid, 2012-2019
Figure 5.32: Market for Novolog/Novorapid by Geography
Figure 5.33: U.S. Market for NovoRapid, 2012-2019
Figure 5.34: Global Market for Victoza, 2012-2019
Figure 5.35: U.S. Market for Victoza, 2012-2019
Figure 5.36: Global Market for Levemir, 2012-2019
Figure 5.37: U.S. Market for Levemir, 2012-2019
Figure 5.38: Global Market for Humalog, 2012-2019
Figure 5.39: U.S. Market for Humalog, 2012-2019
Figure 5.40: Humalog's Market by Geography
Figure 5.41: Global Market for Neulasta, 2012-2019
Figure 5.42: Neulasta's Market Share by Geography
Figure 5.43: U.S. Market for Neulasta, 2012-2019
Figure 5.44: Global Market for Privigen, 2012-2019
Figure 5.45: Global Market for Perjeta, 2012-2019
Figure 5.46: Global Market for Xgeva/Prolia, 2012-2019
Figure 5.47: U.S. Market for Xgeva/Prolia, 2012-2019
Figure 5.48: Global Market for Soliris, 2012-2019
Figure 5.49: U.S. Market for Soliris, 2012-2019
Figure 5.50: Global Market for Botox, 2012-2019
Figure 5.51: U.S. Market for Botox, 2012-2019
Figure 5.52: Global Market for Lucentis, 2012-2019
Figure 5.53: U.S. Market for Lucentis, 2012-2019
Figure 5.54: Global Market for Eylea, 2012-2019
Figure 5.55: U.S. Market for Eylea, 2012-2019
Figure 5.56: Global Market for Avastin, 2012-2019
Figure 5.57: U.S. Market for Avastin, 2012-2019
Figure 5.58: Global Market for Rituxan, 2012-2019
Figure 5.59: Rituxan's Market Share by Geography
Figure 5.60: U.S. Market for Rituxan, 2012-2019
Figure 5.61: Global Market for Revlimid, 2012-2019
Figure 5.62: U.S. Market for Revlimid, 2012-2019
Figure 5.63: Global Market for Herceptin, 2012-2019
Figure 5.64: Herceptin's Market Share by Geography
Figure 5.65: U.S. Market for Herceptin, 2012-2019
Figure 5.67: Global Market for Prenvar 13, 2012-2019
Figure 5.68: U.S. Market for Prenvar 13, 2012-2019
Figure 5.69: Global Market for Gardasil, 2012-2019
Figure 5.70: U.S. Market for Gardasil, 2012-2019
Figure 5.71: Global Market for Fluzone/Varigrip, 2012-2019
Figure 5.72: Global Market for Varivax, 2012-2019
Figure 5.73: U.S. Market for Varivax, 2012-2019
Figure 5.74: Global Market for Stelara, 2012-2019
Figure 5.75: U.S. Market for Stelara, 2012-2019
Figure 5.76: Global Market for Actemra, 2012-2019
Figure 5.77: Global Market for Gammagard Liquid, 2012-2019
Figure 5.78: U.S. Market for Gammagard Liquid, 2012-2019
Figure 5.79: U.S. Market for Biologic Drugs, 2007-2012
Figure 5.80: The Leading Biologic Drug Classes in Terms of U.S. Sales
Figure 5.81: Top Selling Biologic Drugs in the U.S.
Figure 5.82: U.S. Sales of Biologics by Manufacturer
Figure 5.83: U.S. Sales of mAbs
Figure 5.84: U.S. Sales of Recombinant Hormones
Figure: 5.85: U.S. Sales of Blood Cell Growth Factors
Figure 5.86: U.S. Sales of Cytokines 5.16.10
Figure 5.87: U.S. sales of Blood Factors
Figure 5.89: U.S. Sales of Therapeutic Enzymes
Figure 5.90: U.S. Sales of Recombinant Vaccines
Figure 5.91: U.S. Sales of Recombinant Anticoagulants
Figure 5.92: Market for Biologics in Europe, 2012-2019
Figure 5.93: Uptake of Biologics in Europe by Drug Type
Figure 5.94: European Market for mAbs
Figure 5.95: Hemophilia Market Share by Company, 2016
Figure 6.1: Core Therapy Areas for Biosimilars
Figure 6.2: Biosimilars' Market by Geography/Country
Figure 6.3: Top Players in Biosimilars Market
Figure 6.4: Number of Biologics per Indication to Go Off Patent prior to 2020
Figure 6.5: Patent Expiration of leading mAbs
Figure 6.6: Biosimilar mAbs in Pipeline
Figure 6.7: Disease Indications for Biosimilar mAbs Currently in Clinical Trials
Figure 6.8: Global Leaders in Biosimilars, 2012
Figure 6.9: Projected Biosimilars Market Split ($10 Billions) in 2015
Figure 6.10: The Exploding Global Biosimilars Market, 2012-2020
Figure 6.11: Estimated Value and Growth Rates for Biosimilars by Type, 2015
Figure 6.12: Global Spending (%) for Biosimilars by Drug Type ($2.5 Billion), 2015
Figure 6.13: Biosimilars Market in the U.S., 2011-2019
Figure 6.14: HGH Biosimilars in the U.S. Market, June 2009-September 2012
Figure 6.15: Projected U.S. Spend on 11 Specific Biologics, 2012-2024
Figure 6.16: Biosimilar Launchable Dates in the U.S., 2012-2022
Figure 6.17: Cumulative Worldwide Sales of Reference Products, 2012-2022
Figure 6.18: Geographic Distribution of Biosimilar Companies as of 2013
Figure 6.19: Number of Products by Country as of 2013
Figure 6.20: Biosimilars/Biobetters Companies by Size Range (Revenue $ Billions) Worldwide, 2013
Figure 6.21: Biosimilars Approved in the E.U., 2012
Figure 6.22: Biosimilars Market in Europe and Japan, 2012-2019
Figure 6.23: Annual European Sales of Filgrastim Products, 2010-2012
Figure 6.24: Number of Scientific Advice from EMA by Biosimilars Firms
Figure 6.25: Biosimilars Penetration Rate (%) in Daily G-CSF Class Market, 2012
Figure 6.26: Revenue Forecast for Biosimilar Insulin Glargine in Major Seven Markets, 2009-2020
Figure 6.27: Revenue Forecast for Biosimilar HGH in the Major Seven Markets, 2009-2020
Figure 6.29: Revenue Forecast for Biosimilar IFN Beta Ia in the Major Seven Markets, 2009-2020
Figure 6.30: Revenue Forecast for Biosimilar Filgrastim in the Major Seven Markets, 2009-2020
Figure 6.31: Revenue Forecast for Biosimilar Epoetin Alpha in the Major Seven Markets, 2009-2020
Figure 6.32: Biosimilars Uptake Rates in Europe's Top Five Countries, 2012
Figure 6.33: Market for Biosimilars in China, 2012-2019
Figure 6.34: Biosimilar Market in India, 2008-2012
Figure A.2.1: Percent Change in Hospital Admissions and Office Visits, 2012
Figure A.2.2: Percent Population, Prescriptions and Per Capita Change in Prescriptions by Age
Figure A.2.3: Therapy Areas for Largest Positive and Negative Contribution to Growth
Figure A.2.4: U.S. National Respiratory Illness Estimates, 2010-2013
Figure A.2.5: Per Capita Spending Growth, 2002-2017
Figure A.2.6: Percent of Health Plan Members Ranked by Healthcare Spending ($)
Figure A.2.7: Percent of Health Plan Members Healthcare Spending ($)
Figure A.2.8: Components of Change in Total Spending ($ Billion), 2011-2012
Figure A.2.9: Protected Brand Price Spending Growth, 2008-2012
Figure A.2.10: New Brand Spending ($ Billions)
Figure A.2.11: Percent Share of Prescriptions, 2003-2012
Figure A.2.12: Comparison of Medicine Spending by Segment, 2012
Figure A.2.13: Significant Increase in Consumer-Driven Health Plans Enrollment, 2008-2012
Figure A.2.14: Average Patient Out-of-Pocket Costs by Plan Type, 2008-2012
Figure A.2.15: Average Annual Out-of-Pocket Costs for Deductibles, Co-Pay and Co-Insurance Spend
Figure A.2.16: Percent of Retail Dispensed Prescriptions by Out-of-Pocket Costs ($), 2012
Figure A.2.17: Percent of Retail Dispensed Prescriptions by Out-of-Pocket Costs ($)
Figure A.2.18: New Molecular Entities (NMEs) Launched in the U.S., 2003-2012
Figure A.2.19: New Oncology NME Launches in the U.S., 2003-2012
Figure A.2.20: Spending in Leading Therapy Areas
Figure A.2.21: Oncology Spending by Area
Figure A.2.22: U.S. Market for Oncologics, 2008-2012
Figure A.2.23: U.S. Market for Rituxan, 2008-2012
Figure A.2.24: U.S. Market for Avastin, 2008-2012
Figure A.2.25: Mental Health Spending by Area, 2012
Figure A.2.26: U.S. Market for Mental Health Medicines, 2008-2012
Figure A.2.27: U.S. Market for Cymbalta, 2008-2012
Figure A.2.28: U.S. Market for Abilify, 2008-2012
Figure A.2.29: Respiratory Spending by Area, 2012
Figure A.2.30: U.S. Market for Respiratory Agents, 2008-2012
Figure A.2.31: U.S. Market for Adavair Diskus, 2008-2012
Figure A.2.32: U.S. Market for Sigulair, 2008-2012
Figure A.2.33: Spiriva Handihaler, 2008-2012
Figure A.2.34: Antidiabetes Spending by Area, 2008-2012
Figure A.2.35: U.S. Market for Antidiabetics, 2008-2012
Figure A.2.36: U.S. Market for Januvia, 2008-2012
Figure A.2.37: U.S. Market for Lantus, 2008-2012
Figure A.2.38: U.S. Market for Lantus SoloSTAR, 2008-2012
Figure A.2.39: Pain Spending by Area, 2008-2012
Figure A.2.40: Pain Spending by Area, 2008-2012
Figure A.2.41: U.S. Market for Pain Management Drugs, 2008-2012
Figure A.2.42: U.S. Market for Medicines Used in Nervous System Disorders, 2008-2012
Figure A.2.43: U.S. Market for Oxycontin, 2008-2012
Figure A.2.44: U.S. Market for Lyrica, 2008-2012
Figure A.2.45: U.S. Market for Copaxone, 2008-2012
Figure A.2.46: U.S. Market for Lipid Regulators, 2008-2012
Figure A.2.47: U.S. Market for Crestor, 2008-2012
Figure A.2.48: U.S. Market for Autoimmune Drugs, 2008-2012
Figure A.2.49: U.S. Market for Humira, 2008-2012
Figure A.2.50: U.S. Market for Enbrel, 2008-2012
Figure A.2.51: U.S. Market for Remicade, 2008-2012
Figure A.2.52: U.S. Market for Medicines Used for Multiple Sclerosis, 2008-2012
Figure A.2.53: U.S. Market for Antiulcerants, 2008-2012
Figure A.2.54: U.S. Market for Nexium, 2008-2012
Figure A.2.55: U.S. Market for Neulasta, 2008-2012
Figure A.2.56: U.S. Market for Epogen, 2008-2012
Figure A.2.57: U.S. Market for Platelet Aggregation Inhibitors, 2008-2012
Figure A.2.58: U.S. Market for Plavix, 2008-2012
Figure A.2.59: U.S. Market for HIV Antivirals, 2008-2012
Figure A.2.60: U.S. Market for Atripla, 2008-2012
Figure A.2.61: U.S. Market for Truvada, 2008-2012
Figure A.2.62: U.S. Market for Antibacterials, 2008-2012
Figure A.2.63: U.S. Market for Antihypertensives, Plain & Combo, 2008-2012
Figure A.2.64: U.S. Market for Diovan, 2008-2012
Figure A.2.65: U.S. Market for ADHD, 2008-2012
Figure A.2.66: U.S. Market for Vaccines (Pure, Comb and Others), 2008-2012
Figure A.2.67: U.S. Market for Systemic Hormonal Contraceptives, 2008-2012
Figure A.2.68: Treated Patients in Selected Therapies in the U.S., 2012
Figure A.4.1: Ranking of Asian Territories across All Factors
Figure A.4.2: Cost Ranking of Asian Territories
Figure A.4.3: Market Opportunity Ranking of Asian Territories
Figure A.5.1: Steady Increase of Biologics as a Share of Total FDA Approval
Figure A.5.2: Proportion of Health Insurers with Plans for Implementing Novel Contracting Models
Figure A.5.3: Insurer Expectations of Clinical and Cost Evidence from the Pharma for Formulary Placement
Figure A.5.4: Data on Total U.S. Prescription Drug Spending
Figure A.5.5: Need for Aligned Efforts of Providers, Payers and Patients for Better Patient Outcomes
Figure A.5.6: Number of Companion Diagnostics Partnerships with Pharma
Figure A.5.7: Payer's Perceived Barriers to Novel Contracting Practices
Figure A.5.8: Current and Future State of Data Conversions and Analysis
Figure A.5.9: Sources of Influence for Formulary Coverage and Decision Making
Figure A.6.1: Medical Cost Trend, 2010-2013
Figure A.6.2: Private Health Insurance Benefits by Spending Category
Figure A.6.3: Percent of U.S. Patients Seeking Treatment in Retail Clinics
Figure A.6.4: Surgical Cosmetic Procedures in the U.S.
Figure A.6.5: Increase in High-Cost Insurance Claims
Figure A.6.6: Percentage of Individuals with Employer-Sponsored Coverage in a High-Deductible Plan with a Savings Option
Figure A.6.7: Percentage of Consumers Delaying Care Because of Cost

INDEX OF TABLES

Table 2.1: R&D Spending by Top 20 Companies, 2012-2018
Table 2.2: Top 20 Most Valuable Pharmaceutical R&D projects, 2018
Table 2.3: Most Valuable R&D Projects (Ranked by NPV), May 2012 and Current
Table 2.4: FDA Approval Count (NMEs & Biologics) vs. Fifth Year after Launch U.S. Product Sales
Table 2.5: Top Ten NMEs of 2012 Ranked by U.S. Consensus Sales in 2017
Table 2.6: Increasing Demand for Pharmaceuticals in Emerging Markets
Table 2.7: Top Ten Global Pharmaceutical Firms, 2011-2012
Table 2.8: Top Ten Pharmaceuticals by Sales in 2012
Table 2.9: Worldwide Prescription and OTC Sales by Therapy Area in 2018
Table 2.10: Top Ten Companies in Global Oncology Sales, 2012-2018
Table 2.11: Top Five Oncology Product Sales, 2018
Table 2.12: Top Ten Companies and Global Antidiabetic Sales, 2012-2018
Table 2.13: Top Five Anti-Diabetic Products, 2018
Table 2.14: Top Ten Companies and Global Anti-Rheumatic Sales, 2012-2018
Table 2.15: Top Five Anti-Rheumatic Products, 2012-2018
Table 2.16: Top Ten Companies and Total Global Vaccine Sales, 2012-2018
Table 2.17: Top Five Vaccine Products, 2018
Table 2.18: Top Ten Companies and Total Global Anti-Viral Sales, 2012-2018
Table 2.19: Top Five Anti-Viral Products, 2018
Table 2.20: Top 50 Global Pharmaceutical Brands in 2018
Table 2.21: M&A Transactions in 2012
Table 2.22: U.S. Prescription Drug Sales by Top 20 Companies, 2010-2012
Table 2.23: Top 50 Pharmaceutical Products in the U.S., 2012
Table 2.24: Top 50 Pharmaceutical Brands in the U.S. in 2018
Table 2.25: Prescription Drug Sales in Europe by Top 20 Companies, 2010-2012
Table 2.26: Prescription Drug Sales in Japan by the Top 20 Companies, 2010-2012
Table 2.27: Regional Prescription Drug Sales in the U.S., Europe and Japan (Top 20 Companies), 2012
Table 3.1: Patent Expiries by Country and Year, 2011-2015
Figure 3.2: Top 25 Companies by R & D Pipeline Size, 2012
Table 3.3: Top 25 Therapeutic Categories in R & D, 2011-2012
Table 3.4: Top 25 Individual Diseases in the R & D Pipeline, 2012
Table 3.5: Top 20 Mechanism of Action in 2012 R&D Pipeline
Table 3.6: Top 25 Drug Protein Targets in 2012 R&D Pipeline
Table 4.1: Top 20 Companies in Global Generics Sales, 2012
Table 5.1: Number of Biologics Available in the Global Market
Table 5.2: Global Sales of Top 12 Biologics ($67 Billion), 2012
Table 5.3: Patent Protection for Roche's Biologics
Table 5.4: Humira's Revenues, Growth Rate and Market Share, 2010-2015
Table 5.6: Humira's Revenues, Growth Rate and Market Share, 2016-2022
Table 5.7: Top U.S. Biotech Companies Ranked by Revenue, 2011-2012
Table 5.8: Sales if Neulasta/Neupogen, 2010-2012
Table 5.9: U.S. Biotechnology at a Glance, 2011-2012
Table 5.10: R & D Investment by the Top Ten Biotech Companies in the U.S., 2010-2012
Table 5.11: Cost of Commonly Used Biologics in the U.S.
Table 5.12: Biologics Used for Treating Rheumatoid Arthritis
Table 5.13: Biologics and Their Mode of Administration for Arthritis Patients
Table 5.14: Cost Comparison of Arthritis Biologics
Table 5.15: Total Hemophilia Market, 2011-2016
Table 5.16: Hemophilia A (Factor VIII) and von Willebrand Disease, Sales from Marketed Products and Late-Stage Pipeline, 2012-2016
Table 5.17: Hemophilia B, Marketed Products and Late Stage Pipeline, 2012-2016
Table 5.18: The Inhibitor Market: Products and Pipeline
Table 6.1: Definitions of Biosimilar Products
Table 6.2: Biosimilar Pipeline in the U.S.
Table 6.3: Other Key Players in Biosimilars Space
Table 6.4: Patent Expiration for Major Biologics
Table 6.5: Development Status of mAbs Biosimilars
Table 6.6: Generic Companies Active in Biosimilar Space
Table 6.7: Biosimilars Pipeline by Class, 2012
Table 6.8: Market Exclusivity Period for Specific Biologics in the U.S.
Table 6.9: Selected Biosimilars and Biobetters Currently in Development as of 2013
Table 6.10: Companies with the Largest Biosimilar Portfolios as of 2013
Table 6.11: Biosimilars Approved by the E.U.
Table 6.12: Native mAbs Developers in China
Table 6.13: Domestic Biosimilar Developers in India
Table 6.14: Celtrion's Biosimilar Pipeline
Table 6.15: Summary of Publicly Announced Biosimilar Product Transactions Through 2012
Table 7.1: Selected Generics from Apotex
Table 7.2: AstraZeneca's Development Projects
Table 7.3: Patent Expiries of AstraZeneca's Key Marketed Products
Table 7.4: Plasma Derivatives from Bharat Serums and Vaccines Limited
Table 7.5: Biogen Idec's Product Pipeline
Table 7.6: Bristol's Key Products
Table 7.7: Reddy's Product List
Table 7.8: New Products Launched by Richter in Hungary
Table 7.9: New Products Launched by Richter in Central and Eastern Europe
Table 7.10: GSK's Prescription Medicines
Table 7.11: Key Products from Intas
Table 7.12: Merck's Key Pharmaceutical Products
Table 7.13: Pfizer's Major Biopharmaceutical Products
Table A.1.1: Biologic Medicines by Development Phase, 2013
Table A.2.1: List of NMEs Launched in 2012
Table A.2.2: Other NMEs Launched in 2012
Table A.2.3: Top Therapeutic Classes by Prescriptions, 2008-2012
Table A.2.4: Top Medicines by Prescriptions in the U.S., 2008-2012
Table A.3.1: Pharmaceutical Deals in 2012

Note: Product cover images may vary from those shown
Global Biologic Drugs Market to Jump to Over $220 Billion by 2019

- AbbVie, Inc
- Abbott Laboratories
- Actelion Ltd
- Amgen, Inc
- Amoytop Biotech Co, Ltd
- Anhui Anke Biotechnology (Group) Co, Ltd
- Apotex, Inc
- Astellas Pharma, Inc
- AstraZeneca
- Bayer AG
- Beijing Four Rings Biopharmaceuticals
- Bharat Serums and Vaccines Limited
- Bio, Inc
- Biocon Ltd
- Biogen Idec, Inc
- Bioton SA
- Boehringer Ingelheim Pharmaceuticals, Inc
- Bristol-Myers Squibb, Co
- Celgene Corporation
- Celltrion, Inc
- Cipla Ltd
- Dr Reddy's Laboratories Ltd
- Elan Corporation, PLC
- Eli Lilly & Co
- Gideon Richter
- Gilead Sciences, Inc
- GlaxoSmithKline PLC
- Hospira, Inc
- Intas Pharmaceuticals Limited
- Johnson & Johnson
- Merck & Co, Inc
- Mylan, Inc
- Novartis AG
- Pfizer, Inc
- Roche Holdings AG
- Sandoz International GmbH
- Sanofi
- Stada Arzneimittel Aktiengesellschaft
- Teva Pharmaceutical Industries Limited
- Watson Pharmaceuticals, Inc

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos